

# Clinical consequences of Aspergillus disease in cystic fibrosis

<b>Submission date</b> 21/11/2017	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 22/03/2018	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 22/03/2018	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Cystic fibrosis (CF) is a genetic disease which affects the whole body, but respiratory/lung disease is the most prominent problem. Patients with CF are colonised by different bacteria and fungi which can cause lung disease of varying severity, and one of these bugs is the fungus *Aspergillus*. *Aspergillus* is a fungus that is found in the environment, and while people with normal lungs and immune system are not affected by the fungus, CF patient's lungs are particularly vulnerable to infection. There are four potential types of *Aspergillus* disease in CF which have been recently described in a previous study and the health consequences of these types of disease are not well known in comparison to each other. The aim of this study is to look back at the patients involved in the original study that proposed the four types of *Aspergillus* disease and investigate the decline in health and survival outcomes for each type. Patients may change disease type over time, therefore patients from the previous study are re-tested and re-diagnosed as an *Aspergillus* disease type to investigate this. As *Aspergillus* is found in the environment the levels of *Aspergillus* found in the air both in the CF unit and in patient's homes are measured using environmental sampling to understand more about the risks of acquiring *Aspergillus* lung disease, and the effects of ventilation in potentially reducing environmental levels.

### Who can participate?

Cystic fibrosis patients aged over 18 who were involved in the previous study to classify *Aspergillus* disease are approached to be involved in this study

### What does the study involve?

Participants have a blood sample and a sputum sample taken to re-test for *Aspergillus* disease type. These tests are done as part of a CF patient's normal care and do not require an extra trip to the hospital. Patients are also given the option to have their home air tested for the presence of *Aspergillus*, and this is done by the doctor at a home visit of less than 30 minutes.

### What are the possible benefits and risks of participating?

The benefit of taking part in this study is to help increase knowledge of *Aspergillus* disease in CF. No risks are foreseen.

Where is the study run from?

The Manchester Adult Cystic Fibrosis Centre in Wythenshawe Hospital in Manchester (UK)

When is the study starting and how long is it expected to run for?

September 2016 to September 2018

Who is funding the study?

Manchester Adult Cystic Fibrosis Centre (UK)

Who is the main contact?

Dr Lisa Collier

[lisa.collier@mft.nhs.uk](mailto:lisa.collier@mft.nhs.uk)

## Contact information

### Type(s)

Scientific

### Contact name

Dr Lisa Collier

### Contact details

Manchester Adult Cystic Fibrosis Centre

Manchester University NHS Foundation Trust

Wythenshawe Hospital

Southmoor Road

Manchester

United Kingdom

M23 9LT

+44 (0)161 291 4321

[lisa.collier@mft.nhs.uk](mailto:lisa.collier@mft.nhs.uk)

## Additional identifiers

### Integrated Research Application System (IRAS)

232722

### Protocol serial number

IRAS232722

## Study information

### Scientific Title

Clinical consequences of Aspergillus colonisation and disease in cystic fibrosis and the role of environment in acquisition and infection

### Acronym

AspCF

### Study objectives

Aspergillus disease in cystic fibrosis can be classified into four phenotypes (1. No disease, 2. Allergic bronchopulmonary aspergillosis, 3. Aspergillus sensitised, 4. Aspergillus bronchitis). The diagnostic criteria for these classifications was outlined by Baxter et al. 2013 and the same patient cohort used in this study will be followed up to 9 years to review clinical consequences of each class of disease, survival outcomes, and be prospectively re-classified to ascertain whether patient change disease class over time.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

North West - Liverpool East - submission pending

### **Study design**

Single-centre longitudinal cohort study

### **Primary study design**

Observational

### **Study type(s)**

Diagnostic

### **Health condition(s) or problem(s) studied**

Pulmonary Aspergillus disease in patients with cystic fibrosis

### **Interventions**

Patients involved in the previous trial which classified aspergillus disease by phenotype (REC ref: 07/Q1403/70) will followed up to the current day to monitor clinical outcomes and clinical decline, in order to compare the severity of each phenotype. The surviving patients will be approached to consent to reclassification of Aspergillus disease by means of blood test for Aspergillus IgE, Aspergillus IgG, Total IgE and Galactomannan, along with a sputum sample for Aspergillus. These tests form regular follow up of these patients and will not require hospital appointments above their usual outpatient follow up. They will also be asked if they will consent to environmental air sampling of their home either by drop plates being sent to them and/or microbial air sampling. Patients can choose to consent to either or both re-classification and environmental sampling.

### **Intervention Type**

Other

### **Primary outcome(s)**

1. Diagnosis of Aspergillus phenotype by means of blood test for Aspergillus IgE, Aspergillus IgG, Total IgE and Galactomannan, along with a sputum sample for Aspergillus, both at baseline . This is compared to previous phenotype diagnosed in study REC ref: 07/Q1403/70 to establish if change in disease class has occurred
2. Comparison of survival outcomes between class 1-4 of Aspergillus disease (present day snapshot of the patient population), and rate of clinical decline (marked by FEV1 % predicted and BMI measurements taken yearly)

### **Key secondary outcome(s)**

Aspergillus/fungal exposure at a patient's residence, determined by environmental sampling at baseline. This will supplement data collected as part of air quality surveys undertaken in the cystic fibrosis unit, both in inpatient and outpatient areas

**Completion date**

30/09/2018

## Eligibility

**Key inclusion criteria**

All patients will have taken part in study REC ref: 07/Q1403/70 between 2008-2011 (number = 129). Surviving patients who have not received a lung transplant or moved away from the unit since that time will be eligible for prospective reclassification of Aspergillus disease. All 129 patients will be followed up for retrospective data.

1. Cystic fibrosis patients > 18 years old, both male and female
2. Patients who have taken part in study REC ref: 07/Q1403/70
3. Patients eligible for reclassification of Aspergillus disease if not undergone lung transplantation or not moved away from area

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Non cystic fibrosis patients
2. Patients not involved in study REC reference number 07/Q1403/70
3. Patients who have undergone lung transplantation
4. Patients who have moved away from the area during follow-up time from original study

**Date of first enrolment**

01/01/2018

**Date of final enrolment**

30/09/2018

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Wythenshawe Hospital**

Manchester University NHS Foundation Trust

Southmoor Road

Wythenshawe

Manchester

United Kingdom

M23 9LT

## Sponsor information

**Organisation**

Wythenshawe Hospital, Manchester University NHS Foundation Trust

**ROR**

<https://ror.org/00he80998>

## Funder(s)

**Funder type**

Hospital/treatment centre

**Funder Name**

Manchester Adult Cystic Fibrosis Centre

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Andrew Jones.

**IPD sharing plan summary**

Available on request